We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post Transplant Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00395902
First Posted: November 6, 2006
Last Update Posted: December 28, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Amgen
  Purpose
Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients

Condition Intervention
Kidney Tansplant Secondary Hyperparathyroidism Hyperparathyroidism Drug: Sensipar after Post Transplant

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients

Resource links provided by NLM:


Further study details as provided by Amgen:

Estimated Enrollment: 50
Study Start Date: August 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Adults >= 18 years old
  • Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion Criteria:

  • Subjects who received Sensipar before undergoing a kidney transplant
  • Subjects receiving dialysis post-transplant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00395902


Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Global Development Leader, Amgen Inc.
ClinicalTrials.gov Identifier: NCT00395902     History of Changes
Other Study ID Numbers: 20040261
2004261
First Submitted: November 2, 2006
First Posted: November 6, 2006
Last Update Posted: December 28, 2007
Last Verified: December 2007

Keywords provided by Amgen:
Sensipar
cinacalcet
Mimpara

Additional relevant MeSH terms:
Hyperparathyroidism
Hyperparathyroidism, Secondary
Parathyroid Diseases
Endocrine System Diseases
Cinacalcet Hydrochloride
Calcimimetic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs